Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 312000 shares changing hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Performance
The firm has a 50-day moving average of C$0.01 and a two-hundred day moving average of C$0.02. The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The company has a market capitalization of C$1.33 million, a PE ratio of -1.00 and a beta of -0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last posted its quarterly earnings data on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.16 million during the quarter. Research analysts anticipate that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Intel: Is Now the Time to Be Brave?Â
- How to Calculate Inflation Rate
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
